Registry Following Adults With Diabetes, Blood Pressure, Heart or Kidney Disease
Records how adults with type 2 diabetes, hypertension, heart failure or kidney disease are managed.
Key facts
- Who runs it
- AstraZeneca
- Where
- Iztapalapa, León, México, and Mexico City, MexicoSee the 4 sitesAlso in 19 other countries, 62 sites
- Trial code
- Registry title
- iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
- Status
- Recruiting
- People taking part
- 35,000 people, planned
- Started
- 17 Feb 2018
- Expected to end
- 31 Dec 2030
- Type of study
- Observational, 4 groups
- Record updated
- 9 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults with type 2 diabetes, high blood pressure, heart failure and/or chronic kidney disease. It collects real-world data on their care.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Type 2 diabetes, hypertension, heart failure and/or chronic kidney disease
Main reasons for not taking part
- A life-threatening illness with life expectancy below 1 year
- Taking part in an interventional trial that requires informed consent
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Being 18 years or older
- Having type 2 diabetes, Hypertension, Heart Failure and/or chronic kidney disease
- Providing written informed consent to participate in the registry
Who cannot take part
- Having a life-threatening co-morbidity with life expectancy below 1 year
- Participating in an interventional trial requiring informed consent
Where in Mexico
Also in 19 other countries, 62 sites
- IztapalapaHospital not named in the registryTaking people
- León, GuanajuatoHospital not named in the registryTaking people
- MéxicoHospital not named in the registryTaking people
- Mexico CityHospital not named in the registryTaking people
About the trial
What the trial wants to find out
To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases
The 4 groups in the trial
- T2DM Cohort
Patients with T2DM as enrollment motif or T2DM as comorbidity
- HTN Cohort
Patients with HTN as enrollment motif or HTN as comorbidity
- CKD Cohort
Patients with CKD as enrollment motif or CKD as comorbidity
- HF Cohort
Patients with HF as enrollment motif or HF as comorbidity
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases
- Plain-language title
- Registry Following Adults With Diabetes, Blood Pressure, Heart or Kidney DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Uncontrolled Hypertension in Cardio-Renal-Metabolic Diseases: Real-World Insights on Patient Profiles and Management Patterns From iCaReMe Global Registry.International journal of hypertension, 2026
- Record updated
- 9 September 2026